Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
9 Meters Biopharma IncAdvanced Innovative Partners Inc
Allander Biotechnologies LLC
Aqualung Therapeutics Corp
BCN Biosciences LLC
Beijing Puqi Pharmaceutical Technology Co Ltd
BioCurity Pharmaceuticals Inc
BioIncept LLC
BloodCenter of Wisconsin
Bolder Biotechnology Inc
Cellphire Inc
Ceramedix Holding LLC
Ceramide Therapeutics LLC
Chiesi Farmaceutici SpA
Chrysalis BioTherapeutics Inc
Clevexel Pharma SA
Consegna Pharma Inc
Creative Medical Technology Holdings Inc
Devonian Health Group Inc
DMK Pharmaceuticals Corp
Enzychem Lifesciences Corp
EpicentRx Inc
Exponential Biotherapies Inc
Extend Biosciences Inc
F3 Platform Biologics Inc
Fibroplate Inc
Foresee Pharmaceuticals Co Ltd
Genome Protection Inc
GNI Group Ltd
Humanetics Corp
Institute of Cancer Research
iNtRON Biotechnology Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Topcel-KH Pharmaceutical Co Ltd
Lawrence Berkeley National Laboratory
Lutris Pharma
Luxena Pharmaceuticals Inc
Meabco AS
Medesis Pharma SA
Myelo Therapeutics GmbH
National Jewish Health
NeoImmuneTech Inc
Neuropathix Inc
New Amsterdam Sciences Inc
Novartis AG
Noveome Biotherapeutics Inc
NYU Langone Health System
Original BioMedicals Co Ltd
Oxacell AG
P2D Inc
Partner Therapeutics Inc
Perpetuum BV
PharmaIN Corp
Pharmaset Ltd
Phoenicia Biosciences Inc
Pluri Inc
RedHill Biopharma Ltd
Regeneus Ltd
RepoCeuticals ApS
RxBio Inc
Shanghai Pharmaceuticals Holding Co Ltd
Softox Solutions AS
SRI International
Statera Biopharma Inc
Sunny Pharmtech Inc
Synedgen Inc
TheraSource LLC
Tonix Pharmaceuticals Holding Corp
University of Pittsburgh
VasoDynamics Ltd
Vera Salus Ricerca Srl
Worphmed Srl
Xequel Bio Inc
Xerient Pharma Ltd